Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was -13.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -73.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Principal Technologies was -13.40% per year. The lowest was -158.80% per year. And the median was -22.80% per year.
Principal Technologies (FRA:JO7) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Principal Technologies 5-Year EBITDA Growth Rate Related Terms
FRA:JO7 vs VEEV, BTSG, TEM: 5-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Principal Technologies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Principal Technologies 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Principal Technologies's 5-Year EBITDA Growth Rate falls into.
Principal Technologies 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of -73.60% mean?
Principal Technologies (FRA:JO7) has a 5-Year EBITDA Growth Rate of -73.60% as of Apr. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Principal Technologies and its competitors.
Is Principal Technologies' 5-Year EBITDA Growth Rate too high?
Principal Technologies' current 5-Year EBITDA Growth Rate is -73.60%. Overall, Principal Technologies has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Principal Technologies' 5-Year EBITDA Growth Rate compare to VEEV and BTSG?
Principal Technologies' 5-Year EBITDA Growth Rate of -73.60% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Principal Technologies and its competitors. Principal Technologies's current 5-Year EBITDA Growth Rate is -73.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Principal Technologies stock overvalued right now?
Based on GuruFocus' analysis, Principal Technologies (FRA:JO7) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.23 — trading 480% above its estimated fair value. The current 5-Year EBITDA Growth Rate is -73.60%. Principal Technologies' overall GF Score™ is 12/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Principal Technologies (FRA:JO7), the current 5-Year EBITDA Growth Rate is -73.60% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Principal Technologies (FRA:JO7) Overvalued in 2026?
Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued.
The current stock price of €0.23 is trading 480% above its estimated GF Value™ of €0.04.
GuruFocus considers Principal Technologies to be Significantly Overvalued.
Key valuation signals for FRA:JO7:
5-Year EBITDA Growth Rate: -73.60%
GF Value™: €0.04 vs. price of €0.23 (480% above fair value)
No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
12GF Score
Get the complete analysis for FRA:JO7
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JO7 has been successfully added to your 
